Ahmed Fathala1, Mohammed Alqattan1, Riyadh Alsalloum1. 1. Department of Radiology, Nuclear Medicine and Cardiovascular Imaging, King Faisal Specialist Hospital & Research Center P. O Box 3354, Riyadh, Saudi Arabia.
Abstract
OBJECTIVE: This study examined the diagnostic accuracy of myocardial perfusion scintigraphy (MPS) in end-stage renal disease (ESRD) patients and the incidence and clinical and biochemical predictors of myocardial perfusion abnormalities. METHODS: We evaluated 500 asymptomatic ESRD patients on hemodialysis referred for MPS for cardiac risk stratification before renal transplant surgery. Patients with abnormal MPS and an additional few patients without abnormal MPS underwent invasive coronary angiography (ICA). RESULTS: Sixty-nine patients (13%) showed abnormal MPS (reversible or fixed defect). The majority of patients had cardiovascular risk factors. There were statistically significant differences in age, male gender, hypertension, diabetes, hypercholesterolemia, and left ventricular ejection fraction (LVEF) (P < 0.05 for each) between patients with normal and abnormal MPS. Multivariate regression analysis showed that age (≥ 62 years) and low LVEF (≤ 47%) were independent predictors for abnormal MPS. ICA was performed in 112 subjects; the sensitivity, specificity, positive predictive value, and negative predictive value of MPA to detect CAD is 72%, 70%, 79%, and 61%, respectively. CONCLUSIONS: In ESRD, the incidence of myocardial perfusion defects is 13%. In addition to other traditional CAD risk factors, such as diabetes and hypertension, age, and LVEF are the strongest predictors of MPS abnormalities. Initial risk stratification can be cost-effective for identifying high-risk patients who will benefit from more imaging with CAD risk factors and LVEF. In ESRD patients, MPS diagnostic performance is relatively poor. To further evaluate the utility of MPS in diagnosis and risk stratification in ESRD, more data is therefore required. AJCD
OBJECTIVE: This study examined the diagnostic accuracy of myocardial perfusion scintigraphy (MPS) in end-stage renal disease (ESRD) patients and the incidence and clinical and biochemical predictors of myocardial perfusion abnormalities. METHODS: We evaluated 500 asymptomatic ESRDpatients on hemodialysis referred for MPS for cardiac risk stratification before renal transplant surgery. Patients with abnormal MPS and an additional few patients without abnormal MPS underwent invasive coronary angiography (ICA). RESULTS: Sixty-nine patients (13%) showed abnormal MPS (reversible or fixed defect). The majority of patients had cardiovascular risk factors. There were statistically significant differences in age, male gender, hypertension, diabetes, hypercholesterolemia, and left ventricular ejection fraction (LVEF) (P < 0.05 for each) between patients with normal and abnormal MPS. Multivariate regression analysis showed that age (≥ 62 years) and low LVEF (≤ 47%) were independent predictors for abnormal MPS. ICA was performed in 112 subjects; the sensitivity, specificity, positive predictive value, and negative predictive value of MPA to detect CAD is 72%, 70%, 79%, and 61%, respectively. CONCLUSIONS: In ESRD, the incidence of myocardial perfusion defects is 13%. In addition to other traditional CAD risk factors, such as diabetes and hypertension, age, and LVEF are the strongest predictors of MPS abnormalities. Initial risk stratification can be cost-effective for identifying high-risk patients who will benefit from more imaging with CAD risk factors and LVEF. In ESRDpatients, MPS diagnostic performance is relatively poor. To further evaluate the utility of MPS in diagnosis and risk stratification in ESRD, more data is therefore required. AJCD
Authors: Rami Doukky; Nathan Frogge; Yohannes A Bayissa; Gautam Balakrishnan; Jacob M Skelton; Kara Confer; Kalindi Parikh; Russell F Kelly Journal: J Nucl Cardiol Date: 2013-08-09 Impact factor: 5.952
Authors: W E Braun; D F Phillips; D G Vidt; A C Novick; S Nakamoto; K L Popowniak; E Paganini; M Magnusson; M Pohl; D R Steinmuller Journal: Transplant Proc Date: 1984-06 Impact factor: 1.066
Authors: Fadi G Hage; Stuart Smalheiser; Gilbert J Zoghbi; Gilbert J Perry; Mark Deierhoi; David Warnock; Ami E Iskandrian; Angelo M de Mattos; Raed A Aqel Journal: Am J Cardiol Date: 2007-07-05 Impact factor: 2.778
Authors: Michael Ragosta; Habib Samady; Ross B Isaacs; Lawrence W Gimple; Ian J Sarembock; Eric R Powers Journal: Am Heart J Date: 2004-06 Impact factor: 4.749
Authors: R K Patel; P B Mark; N Johnston; R McGeoch; M Lindsay; D B Kingsmore; H J Dargie; A G Jardine Journal: Am J Transplant Date: 2008-05-28 Impact factor: 8.086
Authors: Mark J Sarnak; Kerstin Amann; Sripal Bangalore; João L Cavalcante; David M Charytan; Jonathan C Craig; John S Gill; Mark A Hlatky; Alan G Jardine; Ulf Landmesser; L Kristin Newby; Charles A Herzog; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Thomas H Marwick Journal: J Am Coll Cardiol Date: 2019-10-08 Impact factor: 24.094